GlassScriptPhysician profile
Teah M Dewitt
NPI 1245092352
$2,869.85
in general payments reported to CMS, 2019-2025
16 companies · $2,846 in 2025
The $2,846 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $24.22 · 2025: $2,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,827 · Education: $42.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,826.86 |
| Education | $42.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $397.89 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $389.31 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $344.11 | 2024-2025 | |
| Genzyme Corporation | $325.77 | 2025 | |
| Abbvie INC. | $283.61 | 2025 | |
| Pfizer INC. | $213.86 | 2025 | |
| Ucb, INC. | $174.05 | 2025 | Bimzelx |
| Galderma Laboratories, L.P. | $161.99 | 2025 | Nemluvio |
| Amgen INC. | $160.43 | 2025 | Otezla |
| Arcutis Biotherapeutics, INC. | $109.04 | 2025 | Zoryve |
| Organon LLC | $86.69 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $81.38 | 2025 | |
| Sun Pharmaceutical Industries INC. | $80.09 | 2025 | |
| Lilly USA, LLC | $24.02 | 2025 | Ebglyss |
| Leo Pharma INC. | $20.25 | 2025 | Anzupgo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $17.36 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teah Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.